Active TMS for Alzheimer Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer Disease
CILT - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether transcranial magnetic stimulation (TMS) combined with Constraint Induced Language Therapy (CILT) can improve verbal communication in patients with Alzheimer Disease (AD).

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 6-months post-treatment

6-months post-treatment
Change in PNT
Change in WAB-AQ

Trial Safety

Trial Design

2 Treatment Groups

Active TMS
1 of 2
Sham TMS
1 of 2

Active Control

Non-Treatment Group

30 Total Participants · 2 Treatment Groups

Primary Treatment: Active TMS · Has Placebo Group · Phase 1

Active TMSActiveComparator Group · 2 Interventions: CILT, Active TMS · Intervention Types: Behavioral, Device
Sham TMSShamComparator Group · 2 Interventions: CILT, Sham TMS · Intervention Types: Behavioral, Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6-months post-treatment

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,423 Previous Clinical Trials
24,561,161 Total Patients Enrolled
27 Trials studying Alzheimer Disease
11,336 Patients Enrolled for Alzheimer Disease
University of PennsylvaniaLead Sponsor
1,822 Previous Clinical Trials
41,116,193 Total Patients Enrolled
17 Trials studying Alzheimer Disease
3,780 Patients Enrolled for Alzheimer Disease
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
274 Previous Clinical Trials
174,320 Total Patients Enrolled
4 Trials studying Alzheimer Disease
139 Patients Enrolled for Alzheimer Disease
H. Branch Coslett, MD4.04 ReviewsPrincipal Investigator - University of Pennsylvania
University of Pennsylvania
2 Previous Clinical Trials
107 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: November 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References